Business Description
Nexalis Therapeutics Limited is an Australian biotechnology company focused on developing inhaled medicines that combine drugs with delivery devices. Founded in 2016 and based in Melbourne, the company is advancing two key programs: IRX-211, which has completed early-stage human trials for sudden severe cancer pain, and IRX-616a, which is in early research for panic disorder. Previously operating under the name InhaleRx Limited, the company adopted its current name in January 2026.
